Delivery Order SPE2DB25D3202-SPE2DB25FTBMJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,017.91 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a widely used anticoagulant medication. The contract, awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, employs firm fixed pricing with no set-aside designation, indicating competitive award conditions. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $6,506.70 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a widely used anticoagulant medication. The order was competitively awarded as a firm fixed-price delivery order with no set-aside designation and an ultimate completion date of June 4, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,463.80 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a pharmaceutical product used in anticoagulation therapy. This competitively awarded, firm fixed-price delivery order was issued on August 12, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract includes no set-aside designation, indicating that...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,925.06 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a widely prescribed anticoagulant medication. The award was made on July 31, 2025, with an ultimate completion date of August 1, 2025, under a firm fixed-price contract type with no set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a $9,868.31 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a commonly prescribed anticoagulant medication. This competitive delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, carries firm fixed pricing and represents a child contract under AmerisourceBergen's broader pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $13,065.95 for 60 tablets of Eliquis 5 mg, a widely prescribed anticoagulant medication. This competitive award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, carries a firm fixed price structure with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this delivery order from...
- The Defense Logistics Agency awarded a delivery order valued at $6,601.44 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a widely prescribed anticoagulant medication. The order, issued on September 25, 2025, with an ultimate completion date of September 26, 2025, represents a firm fixed-price delivery under a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a $37,391.10 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a commonly prescribed anticoagulant medication. This contract, effective June 2–3, 2025, was competitively awarded without set-aside provisions and carries firm fixed pricing. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a widely-used anticoagulant medication, with a contract ceiling value of $20,064.90. This competitively-awarded, firm fixed price delivery order was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied...
- The Defense Logistics Agency awarded a $4,929.08 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, a commonly prescribed anticoagulant medication. Issued on August 25, 2025, with an ultimate completion date of August 26, 2025, this firm fixed-price contract represents a competitively awarded, non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTBMJDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $3,931.20 to supply 60 tablets of Eliquis 5 mg, a commonly prescribed anticoagulant medication. The contract, awarded on September 26, 2025, with completion targeted for September 29, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including customers such as the Defense Health Agency and U.S. Coast Guard. The company's pharmaceutical supply portfolio demonstrates extensive capability across multiple therapeutic domains, positioning it as a critical vendor within the federal medical procurement system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 9/26/25 |